WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced an agreement with Genomics England to further collaborate on the Generation Study. Under the new contract, Revvity will now ...
RVTY gains from strong diagnostics demand and fast-growing Signals software, but China policy pressure and weak research spending temper near-term growth.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced the launch of Revvity Transcribe AI, an innovative optical character recognition (OCR) service designed to convert ...
Newborn screening searches for genetic markers in blood or heel prick samples to detect health issues in infants, enabling crucial early intervention that improves long-term outcomes. The advent of ...
Revvity, Inc. RVTY is slated to report fourth-quarter 2024 results on Jan. 31, before market open. In the last reported quarter, the company delivered an earnings surprise of 13.27%. RVTY’s earnings ...
TD Cowen 46th Annual Health Care Conference March 3, 2026 2:30 PM ESTCompany ParticipantsPrahlad Singh - CEO, President ...
Revvity's Dharmacon All-in-one lentiviral platform has expanded to include whole-genome library options for CRISPR knockout (CRISPRko), CRISPR interference (CRISPRi), and CRISPR activation (CRISPRa).
New agreement to support newborn health adds sequencing lab services to the existing extraction services collaboration The Generation Study, a research project spearheaded by Genomics England in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results